| Identification | Back Directory | [Name]
Quinazoline, 4-[1-[(2-bromophenyl)methyl]-2-phenyl-1H-indol-3-yl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- | [CAS]
2470908-79-1 | [Synonyms]
YS-370
Quinazoline, 4-[1-[(2-bromophenyl)methyl]-2-phenyl-1H-indol-3-yl]-7-methoxy-6-[3-(4-morpholinyl)propoxy]- | [Molecular Formula]
C37H35BrN4O3 | [MOL File]
2470908-79-1.mol | [Molecular Weight]
663.6 |
| Chemical Properties | Back Directory | [Boiling point ]
784.8±60.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 8.33 mg/mL (12.55 mM; ultrasonic and warming and heat to 80°C) | [form ]
Solid | [pka]
7.00±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Biological Activity]
YS-370 (compound 44) is a potent, high selective, and orally active inhibitor of P-glycoprotein (P-gp). YS-370 stimulates the P-gp ATPase activity and has moderate inhibition against CYP3A4. YS-370 effectively reverses multidrug resistance (MDR) to paclitaxel and colchicine in SW620/AD300 and HEK293T-ABCB1 cells. YS-370 in combination with paclitaxel achieves much stronger antitumor activity[1]. | [References]
[1]. Yuan S, et al. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. J Med Chem. 2021;64(19):14895-14911. |
|
|